This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (89)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Cardiovascular System  • Congestive Heart Failure/ Cardiomyopathy  • Alert me on articles by topic  Social Bookmarking   What's this?

-Blocker Therapy in Heart Failure

Scientific Review

JoAnne Micale Foody, MD; Michael H. Farrell, MD; Harlan M. Krumholz, MD

JAMA. 2002;287:883-889.

Context  Care of patients with heart failure has been revolutionized throughout the past decade. A paradigm shift in the strategy for treating heart failure caused by systolic dysfunction is in progress. Despite the initial perception about -blockers' safety, they are now the most extensively studied class of agents in the treatment of heart failure and have emerged as an important intervention to improve the clinical outcomes of heart failure patients.

Objective  To provide scientific rationale for the use of -blockers for patients with heart failure.

Data Sources  All English-language articles of large, randomized controlled clinical trials assessing the mortality benefits of -blockers in patients with heart failure were identified to provide the scientific rationale for the use of -blockers in heart failure. Basic science studies were reviewed to provide an overview of the potential physiologic role of -blockers in heart failure. Finally, clinical guidelines for the treatment of patients with heart failure were assessed to determine current recommendations for the use of these agents.

Study Selection and Data Extraction  Randomized controlled clinical trials of -blockers that included more than 300 subjects and assessed mortality as a primary end point.

Data Synthesis  Of the 4 -blockers tested in large randomized controlled clinical trials of patients with heart failure, 3 are available in the United States, bisoprolol, carvedilol, and metoprolol; 2 of these, carvedilol and metoprolol, have Food and Drug Administration indications for the treatment of heart failure. Compared with placebo treatment, -blocker use is associated with a consistent 30% reduction in mortality and a 40% reduction in hospitalizations in patients with class II and III heart failure.

Conclusions  Tested in more than 10 000 patients, -blockers reduce morbidity and mortality in class II through IV heart failure. Along with angiotensin-converting enzyme inhibitors, digoxin, and diuretics, -blockers have strengthened the armamentarium to improve clinical outcomes of heart failure patients. The science supporting -blockers must be translated into practice safely and rationally if the agents are to achieve their full potential.

Author Affiliations: Department of Internal Medicine, Sections of Cardiovascular Medicine (Drs Foody and Krumholz) and General Medicine (Dr Farrell), and the Section of Health Policy and Administration, Department of Epidemiology and Public Health (Dr Krumholz), Yale University School of Medicine, New Haven, Conn; and the Center for Outcomes Research and Evaluation, Yale–New Haven Hospital, New Haven, Conn (Dr Krumholz).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

-Blockers in Heart Failure: Clinical Applications
Michael H. Farrell, JoAnne Micale Foody, and Harlan M. Krumholz
JAMA. 2002;287(7):890-897.
ABSTRACT | FULL TEXT  

February 20, 2002
JAMA. 2002;287(7):921-922.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Ventricular assist devices the challenges of outpatient management.
Wilson et al.
J Am Coll Cardiol 2009;54:1647-1659.
ABSTRACT | FULL TEXT  

Proteasome inhibitors and cardiac cell growth
Hedhli and Depre
Cardiovasc Res 2009;0:cvp226v2-cvp226.
ABSTRACT | FULL TEXT  

Meta-analysis: {beta}-Blocker Dose, Heart Rate Reduction, and Death in Patients With Heart Failure
McAlister et al.
ANN INTERN MED 2009;150:784-794.
ABSTRACT | FULL TEXT  

Exercise haemodynamic variables rather than ventilatory efficiency indexes contribute to risk assessment in chronic heart failure patients treated with carvedilol
Corra et al.
Eur Heart J 2009;0:ehp138v1-ehp138.
ABSTRACT | FULL TEXT  

Levosimendan vs. dobutamine: outcomes for acute heart failure patients on {beta}-blockers in SURVIVE
Mebazaa et al.
Eur J Heart Fail 2009;11:304-311.
ABSTRACT | FULL TEXT  

The current role of beta-blockers in chronic heart failure: with special emphasis on the CIBIS III trial
Willenheimer
Eur Heart J Suppl 2009;11:A15-A20.
ABSTRACT | FULL TEXT  

Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET)
Torp-Pedersen et al.
Heart 2007;93:968-973.
ABSTRACT | FULL TEXT  

An {alpha}1A-Adrenergic-Extracellular Signal-Regulated Kinase Survival Signaling Pathway in Cardiac Myocytes
Huang et al.
Circulation 2007;115:763-772.
ABSTRACT | FULL TEXT  

Utility of Amino-Terminal Pro-Brain Natriuretic Peptide, Galectin-3, and Apelin for the Evaluation of Patients With Acute Heart Failure
van Kimmenade et al.
J Am Coll Cardiol 2006;48:1217-1224.
ABSTRACT | FULL TEXT  

Rationale and design of CIBIS III
Ponikowski
Eur Heart J Suppl 2006;8:C35-C42.
ABSTRACT | FULL TEXT  

Protecting the Heart with Cardiac Medication in Patients with Left Ventricular Dysfunction Undergoing Major Noncardiac Vascular Surgery
Feringa et al.
SEMIN CARDIOTHORAC VASC ANESTH 2006;10:25-31.
ABSTRACT  

Changing Incidence and Survival for Heart Failure in a Well-Defined Older Population, 1970-1974 and 1990-1994
Barker et al.
Circulation 2006;113:799-805.
ABSTRACT | FULL TEXT  

Nesiritide for outpatient treatment of heart failure
Bauer and Randazzo
Am J Health Syst Pharm 2005;62:2639-2642.
FULL TEXT  

Effectiveness of comprehensive disease management programmes in improving clinical outcomes in heart failure patients. A meta-analysis
Roccaforte et al.
Eur J Heart Fail 2005;7:1133-1144.
ABSTRACT | FULL TEXT  

Angiotensin-Converting Enzyme Inhibitors or {beta}-Blockers in Heart Failure: Does It Matter Who Goes First?
Fang
Circulation 2005;112:2380-2382.
FULL TEXT  

Nonexcitatory electrical signals for enhancing ventricular contractility: rationale and initial investigations of an experimental treatment for heart failure
Burkhoff and Ben-Haim
Am. J. Physiol. Heart Circ. Physiol. 2005;288:H2550-H2556.
FULL TEXT  

Pursuing integration of performance measures into electronic medical records: beta-adrenergic receptor antagonist medications
Weiner et al.
Qual Saf Health Care 2005;14:99-106.
ABSTRACT | FULL TEXT  

Heart failure case disease management program: a pilot study of home telemonitoring versus usual care
Capomolla et al.
Eur Heart J Suppl 2004;6:F91-F98.
ABSTRACT | FULL TEXT  

Betablockers in heart failure: Carvedilol Safety Assessment (CASA 2-trial)
Rickli et al.
Eur J Heart Fail 2004;6:761-768.
ABSTRACT | FULL TEXT  

The Use of {beta}-Blockers in a Tertiary Care Heart Failure Clinic: Dosing, Tolerance, and Outcomes
Tandon et al.
Arch Intern Med 2004;164:769-774.
ABSTRACT | FULL TEXT  

Effects of acute and chronic administration of {beta}-adrenoceptor ligands on airway function in a murine model of asthma
Callaerts-Vegh et al.
Proc. Natl. Acad. Sci. USA 2004;101:4948-4953.
ABSTRACT | FULL TEXT  

Pharmacodynamics of{beta}-Blockers in Heart Failure: Lessons from the Carvedilol Or Metoprolol European Trial
Bauman and Talbert
J CARDIOVASC PHARMACOL THER 2004;9:117-128.
ABSTRACT  

Myocardial positron emission computed tomographic images obtained with fluorine-18 fluoro-2-deoxyglucose predict the response of idiopathic dilated cardiomyopathy patients to beta-blockers
Hasegawa et al.
J Am Coll Cardiol 2004;43:224-233.
ABSTRACT | FULL TEXT  

Beta-blockers and angiotensin-converting enzyme inhibitors/receptor blockers prescriptions after hospital discharge for heart failure are associated with decreased mortality in Alberta, Canada
Johnson et al.
J Am Coll Cardiol 2003;42:1438-1445.
ABSTRACT | FULL TEXT  

nNOS gene transfer to RVLM improves baroreflex function in rats with chronic heart failure
Wang et al.
Am. J. Physiol. Heart Circ. Physiol. 2003;285:H1660-H1667.
ABSTRACT | FULL TEXT  

Cardioprotection by Carvedilol: Antiapoptosis is Independent of {beta}-Adrenoceptor Blockage in the Rat Heart
Schwarz et al.
J CARDIOVASC PHARMACOL THER 2003;8:207-215.
ABSTRACT  

Cardiac Resynchronization Therapy Improves Heart Rate Variability in Patients with Symptomatic Heart Failure
Adamson et al.
Circulation 2003;108:266-269.
ABSTRACT | FULL TEXT  

How Do {beta}-Blockers Improve Ventricular Function in Patients With Congestive Heart Failure?
Barry and Gilbert
Circulation 2003;107:2395-2397.
FULL TEXT  

Heart Failure
Jessup and Brozena
NEJM 2003;348:2007-2018.
FULL TEXT  

Analysis of a Large Cohort of Health Maintenance Organization Patients With Congestive Heart Failure
Gladowski et al.
American Journal of Medical Quality 2003;18:73-81.
ABSTRACT  

Continuing Progress in the Treatment of Severe Congestive Heart Failure
Pinski
JAMA 2003;289:754-756.
FULL TEXT  

Altered phosphorylation and Ca2+-sensitivity of myofilaments in human heart failure
Schillinger and Kogler
Cardiovasc Res 2003;57:5-7.
FULL TEXT  

Preoperative {beta}-Blocker Use and Mortality and Morbidity Following CABG Surgery in North America
Ferguson et al.
JAMA 2002;287:2221-2227.
ABSTRACT | FULL TEXT  

{beta}-Blockers in Heart Failure: Clinical Applications
Farrell et al.
JAMA 2002;287:890-897.
ABSTRACT | FULL TEXT